Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

X
Trial Profile

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMMIT
  • Sponsors Satsuma Pharmaceuticals
  • Most Recent Events

    • 15 Jun 2023 According to a Satsuma Pharmaceuticals media release, data from this study selected for presentation at the American Headache Societys (AHS) 65th Annual Scientific Meeting; Full abstracts are now available on the AHS website and will be published in the journal Headache.
    • 18 May 2023 According to a Satsuma Pharmaceuticals media release, results from this trial were announced in November 2022 and subsequently in December 2022.
    • 18 May 2023 Primary endpoint (Freedom From Most-Bothersome Symptom at 2 Hours) has not been met, according to a Satsuma Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top